Goodwin Biotechnology awarded sub-contract for anthrax vaccine

Goodwin Biotechnology, inc., announced on Monday that is was awarded a sub-contract from Emergent BioSolutions to conduct early stage proof-of-concept feasibility for its BioThrax anthrax vaccine.

Anthrax is an acute disease caused by the lethal bacterium Bacillus anthracis. Most versions of the disease are lethal. The anthrax spores can be produced and used as a biological weapon.

BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration. The contract will be used to investigate a possible issue with the process development, which would involve the AVA filtrate for storage process with BioThrax.

"We're excited about the opportunity to contribute our protein purification as well as processing experience and expertise which have been developed and refined over the last 20 years," Muctarr Sesay , vice president of process development at GBI, said. "Our goal is to develop process parameters that are amenable to routine GMP production and large-scale manufacturing in an effort to contribute to the production of BioThrax at large scale."

Goodwin Biotechnology is a CMO that offers Single Source Solution with its partnerships for cell line development. It also offers proof of concept projects throughout process development .

"This phase of process development is critical to our project," Heidi Nielsen , process development engineer of Emergent BioSolutions, said. "We chose to work with Goodwin Biotechnology based on their Quality Systems and experience with large scale, GMP-compliant protein purification and processing."